RATIONALE: Fast dissolving tablets for sublingual allergen immunotherapy (SLIT) are now globally available and cover the three major allergies grass, house dust mite and ragweed. This allows for comparative evaluation of immunological responses to treatment on a global scale across SLIT-tablet development programs. METHODS: Data collected during 8 placebo-controlled phase III studies covering 2509 patients was used for analysis. In all trials, allergen-specific IgE and IgG4 (sIgE and sIgG4) were measured using ImmunoCAP. Active treatment comprised fast-dissolving Zydis-formulation (SLIT-tablets) for allergic rhinitis and/or allergic asthma due to the following allergens: house dust mite (4 trials), grass (2 trials), and ragweed (2 trials). RESULTS: Across trials and allergens, active treatment groups show comparable levels of changes in immunological responses of sIgE and sIgG4. For all trials, the largest average increase in sIgE was observed within the first three months whereas sIgG4 continuously increased during the first year of treatment. For placebo-treated patients, a minor increase in antibody titers in relevant pollen seasons was observed. Looking at individual measurements, consistency was further demonstrated by similar distribution profiles of changes in sIgE and sIgG4 during the early and late phase of treatment, respectively. CONCLUSIONS: During the first year and across trials, changes in sIgE and sIgG4 demonstrate a high level of similarity despite underlying heterogeneity in enrolled patients, tablet treatments and geographical location including Europe, North America and Japan. This indicates a common immunological mechanism for the entire class of fast-dissolving SLIT-tablets. University Hospital of Montpellier, Montpellier, France. RATIONALE: House dust mite (HDM) SLIT-tablet (12 SQ-HDM, ALK, Denmark) has been shown to be effective in treating HDM allergic rhinitis and asthma in DBPC trials. This post-hoc analysis investigates effect of treatment with SQ-HDM SLIT-tablet on sleep in HDM allergic rhinitis. METHODS: Subjects from a Phase III trial (EudraCT: 2011-002277-38; placebo: N5338, 12 SQ-HDM: N5318) with moderate-severe HDM allergic rhinitis were treated for up to 1 year (Demoly et al. 2016;JACI;137:444-51). At baseline and during the course of the trial each subject filled-in the Juniper's RQLQ. 3 sleep parameters (DIFFICULTY getting to sleep, WAKE up during night, LACK of a good night's sleep) were scored from 0 (not troubled) to 6 (extremely troubled). For the purpose of this analysis, scores <3 were categorized into ''mildly affected'' and >53 into ''moderately/severely affected''. RESULTS: Of those moderately/severely affected at baseline (62-72% of the population) only 7-10% remained in that category following treatment with the SQ-HDM tablet. This improvement was significantly better than that observed following treatment with placebo To assess the frequency of SRs to SCIT and identify potential risk factors in our population. METHODS: A retrospective study was performed evaluating individuals who developed SRs while receiving SCIT from 2013-2018. Records of subjects meeting WHO criteria for SRs were reviewed. Frequency, characterization of reactions and demographic information were collected. Individuals with and without SRs were compared. Possible risk factors associated with SRs were evaluated using logistic regression analysis. RESULTS: Systemic reaction rate to SCIT was 0.7% (20 SRs/2,721 injections). Twenty SRs were reported in thirteen individuals. Most reactions were mild, (10 grade 1, 2 grade 2, 7 grade 3 and 1 grade 4) with female predominance (11:2). All individuals received perennial allergens. SRs were common at higher concentrations of allergens (13/20 at 1:1, 6/20 at 1:10, and 1/20 at 1:100). 15/20 reactions were during buildup phase. 9/13 individuals were < 21 years of age. All reactions grade 2 or above received epinephrine. All individuals continued SCIT with dose adjustments. One reaction was caused by medical error. Female sex was the only risk factor for a SR (odds ratio 8.4, p50.010). Being over 21 years old, asthma, drug/food allergy, use of beta blocker or angiotensin converting enzyme inhibitor and higher allergen number were not significantly different between patients with and without SR. CONCLUSIONS: Our rate of SRs during SCIT is slightly higher than published data (0.1%-0.2%). Efforts are needed to improve immunotherapy safety and evaluate the role of perennial allergens and high atopy rate as risk factors to SRs. 
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